| (Values in U.S. Thousands) | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 424,600 | 489,300 | 465,400 | 468,700 | 490,900 |
| Sales Growth | -13.22% | +5.14% | -0.70% | -4.52% | -17.80% |
| Net Income | -249,300 | -249,500 | -284,900 | -257,200 | -119,600 |
| Net Income Growth | +0.08% | +12.43% | -10.77% | -115.05% | +41.37% |
Mallinckrodt Plc (MNKKQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Fiscal Year End Date: 12/31